CDP-choline and citicoline are two names for the same compound. That is the entire point of this page. When you see "CDP-choline" in a research paper and "citicoline" on a supplement bottle, you are not looking at two different substances with two different effects. You are looking at one molecule that has picked up several names over the years, and learning to recognise those names is the first step to reading the evidence without confusion. For the full overview of what citicoline is, see our citicoline hub.
Because this is a naming topic, it has no positive or negative clinical result of its own. The negative results you may have heard about, such as the ICTUS stroke trial and the COBRIT brain injury trial, both of which found no benefit over placebo, belong to those disease pages, not to this one. We keep those separate deliberately. If you want the evidence on any condition citicoline has been studied for, start at our evidence overview rather than assuming the name on the label changes the findings. A capsule labelled "CDP-choline" is governed by exactly the same trials as a capsule labelled "citicoline."
In the United States, citicoline (CDP-choline) is sold as a dietary supplement, not as an FDA-approved drug. Cognizin is a brand name for one particular form of it. None of these differences in naming change what the molecule is.
Evidence at a glance
| Question | Best evidence | Tier | Bottom line |
|---|---|---|---|
| Are CDP-choline and citicoline the same thing? | Naming and chemistry references; both terms are used interchangeably in the trial literature | , | Yes. One compound, several names. |
| Does the name on the label change what the trials found? | Not applicable, this is a label-reading topic, not a disease topic | , | No. Trial results apply to the molecule, whatever the bottle calls it. |
| Is Cognizin something different? | Cognizin is a branded form of citicoline | , | Same compound; the brand funded some of the attention trials. |
| Is it an approved drug in the US? | Regulatory status | , | No. It is sold as a dietary supplement. |
This table is intentionally different from the tables on our condition pages. There is no disease result to report here, because "what is this called?" is not a clinical question. Borrowing a stroke or brain-injury result for a naming page would be misleading, so we have not done it.
Why one compound has so many names
Chemicals often collect names the way people collect nicknames. "CDP-choline" is the older, more chemical-sounding name: it stands for cytidine diphosphate-choline, which describes the molecule's structure. "Citicoline" is the shorter, easier name that became common in medicine and in supplement marketing. Some labels and papers also use "cytidine 5'-diphosphocholine," which is yet another version of the same full chemical name.
The practical consequence is simple: if you search a research database for only one of these names, you will miss studies filed under the other. The large stroke trial ICTUS (Dávalos, *Lancet* 2012, about 2,300 people) and the traumatic brain injury trial COBRIT (Zafonte, *JAMA* 2012) describe the same compound you would buy over the counter, even if the wording differs between papers.
What the names do not tell you
A name on a label tells you what is in the capsule. It does not tell you what the capsule does. This matters because supplement marketing sometimes leans on scientific-sounding names to imply stronger evidence than exists. "CDP-choline" can sound more pharmaceutical than "citicoline," but the trial record, including its well-documented negative results in acute stroke and traumatic brain injury, applies equally to both.
The same caution applies to brand names. Cognizin is a branded ingredient, and it funded the small adult and adolescent attention trials by McGlade and colleagues. Those trials reported better attention-test scores in women taking 250 or 500 mg, and attention and psychomotor speed gains in adolescent males, but they were small and industry funded. A brand name is a marker of who made the ingredient, not proof of extra benefit.
Label-reading in practice
When you pick up a bottle, here is a sensible order of checks:
1. Find the ingredient line. It may say citicoline, CDP-choline, or Cognizin. All three refer to the same compound. 2. Note the dose per capsule. Trials have generally used 250 to 2,000 mg per day, and the compound was generally well tolerated in that range, with mild side effects such as stomach upset, headache, and insomnia. 3. Check what is not said. A US supplement label cannot legally claim to treat a disease. If a label implies it treats ADHD, be aware there are no adequate trials, there is no good evidence citicoline treats ADHD. 4. Think about interactions. Citicoline may enhance the effects of levodopa, so anyone with Parkinson's disease should involve their neurologist before taking it. 5. Know the gaps. Safety data in pregnancy and breastfeeding are lacking.
If you are unsure how to raise any of this with a clinician, our list of questions to ask your doctor about supplements is a good companion to this page.
Expert insight
I want to be plain about what this page is and is not. CDP-choline and citicoline are the same compound, and everything we know about that compound, including the large negative trials in acute stroke and traumatic brain injury, applies no matter which name appears on the label. I have seen how naming confusion leads people to believe they are comparing two products when they are comparing one product with itself. In my view, the honest summary is that the evidence base is mixed: large, well-run trials were negative, while smaller or older studies suggested benefit in areas like chronic cerebrovascular cognitive decline, where a Cochrane review found only modest short-term effects in short, low-quality trials. That record belongs to the molecule, not to the marketing. Read labels for the ingredient, and read the evidence for the condition.
Questions readers ask
Is CDP-choline the same as citicoline?
Yes. They are two names for one compound, and the research literature uses both interchangeably.
Is Cognizin a different substance?
No. Cognizin is a branded form of citicoline. The company behind it funded some of the small attention trials, which is worth knowing when weighing those results.
Does a product labelled "CDP-choline" have different evidence than one labelled "citicoline"?
No. The trials were run on the molecule, not on a brand or a name. That includes the negative results from ICTUS in stroke and COBRIT in traumatic brain injury.
Is citicoline an FDA-approved drug?
In the United States, no. It is sold as a dietary supplement. In some other countries the same compound has been used as a prescription drug, which is one source of the naming confusion.
Why do research papers and supplement bottles use different names?
Historical habit. Chemists and older papers favoured "CDP-choline"; clinicians and marketers favoured "citicoline." Neither group changed the molecule.
Does the name tell me anything about safety?
No, but the trial record does. Citicoline was generally well tolerated at 250 to 2,000 mg per day, with mild side effects like stomach upset, headache, and insomnia. Pregnancy and breastfeeding data are lacking, and it may enhance levodopa's effects, so people with Parkinson's should talk to their neurologist.
Where should I go to read about actual benefits or harms?
To the condition pages and our evidence overview. This page only covers naming; it is not a summary of what citicoline does.
Sources
This naming page draws on the same registered evidence base as the rest of this site, cited here so readers can see that the compound behind every name is the one that was actually studied: ICTUS (Dávalos and colleagues, *Lancet* 2012) in acute stroke; earlier stroke meta-analyses that suggested benefit but were not confirmed by ICTUS; COBRIT (Zafonte and colleagues, *JAMA* 2012) in traumatic brain injury; the Cochrane review by Fioravanti and Yanagi on chronic cerebrovascular cognitive decline; the IDEALE observational study (Cotroneo and colleagues) in mild vascular cognitive impairment; small glaucoma adjunct trials from the Parisi and Rossetti groups; and the Cognizin-funded attention trials by McGlade and colleagues (2012, women; adolescent males). PMIDs are not listed here; each one will be added only after it is individually confirmed on PubMed.
